41. Journal Of Clinical Gastroenterology - UserLogin Portal hemodynamics in chronic portalsystemic encephalopathy Treatment ofpost-shunt portal-systemic encephalopathy by embolization of the shunt. http://www.jcge.com/pt/re/jclngastro/fulltext.00004836-200010000-00019.htm

LWWOnline LOGIN eALERTS REGISTER ... Archive You are attempting to access protected content. To access this content please login using an established account or create/activate an account. If you have already created/ activated an online account, please login below: User Name: Password: Note: passwords are CASE SENSITIVE If you are a new user or guest visiting an LWWonline site for the first time, please complete the new account setup process to view or purchase content. Forgot your password? Subscribe Renewal Information Subscribe to RSS feed utrdc-pt01 Release 4.0

42. Journal Of Clinical Gastroenterology - UserLogin Control of chronic portalsystemic encephalopathy by lactulose. Gut 1969;10416 . Lactulose in the treatment of chronic portalsystemic encephalopathy. http://www.jcge.com/pt/re/jclngastro/fulltext.00004836-199606000-00003.htm

LWWOnline LOGIN eALERTS REGISTER ... Archive You are attempting to access protected content. To access this content please login using an established account or create/activate an account. If you have already created/ activated an online account, please login below: User Name: Password: Note: passwords are CASE SENSITIVE If you are a new user or guest visiting an LWWonline site for the first time, please complete the new account setup process to view or purchase content. Forgot your password? Subscribe Renewal Information Subscribe to RSS feed utrdc-pt02 Release 4.0

43. Liver Cirrhosis disease and cancer).1 Liver cirrhosis may also cause a dangerous brainabnormality called portalsystemic encephalopathy (PSE), which may lead to coma. http://www.truestarhealth.com/Notes/1231004.html

Weight Loss Truestar k i d s Encyclopedia of Health Natural Health Sport - Specific Training News Reel Online Store Hi ! Welcome to Truestar Health. Log In Welcome to the Truestar Health Encyclopedia Welcome to the Truestar Health Encyclopedia –the most comprehensive information database available on health, wellness, food, nutrition, vitamins and supplements. Use of our encyclopedia will enable you to make well-informed, responsible decisions for the promotion of your own health and wellness. Enter search items Liver Cirrhosis Introduction Checklist Symptoms Treatments ... References Cirrhosis is a condition of severe damage to the liver that impairs its ability to function normally. In the United States, the most common cause of liver cirrhosis is chronic alcoholism . Liver cirrhosis may also result from chronic viral infection of the liver ( hepatitis types B, C, and D) and a number of inherited diseases, such as cystic fibrosis , hemochromatosis, and . If severe, liver cirrhosis may lead to liver failure and death. In the Western world, liver cirrhosis is the third leading cause of death in people aged 45 to 65 (after cardiovascular disease and cancer Liver cirrhosis may also cause a dangerous brain abnormality called portal-systemic encephalopathy (PSE), which may lead to coma. Another form of cirrhosis, primary biliary cirrhosis (PBC), damages the bile ducts connecting the liver and gallbladder, and occurs primarily in women over 35 years of age. The cause of PBC is not known.

44. Differentiation Between Portal-systemic Encephalopathy And Neurodegenerative Dis Differentiation between portalsystemic encephalopathy and neurodegenerativedisorders in patients with Wilson disease H-1 MR spectroscopy http://radiology.rsnajnls.org/cgi/content/abstract/203/2/539

HOME HELP FEEDBACK SUBSCRIPTIONS ... TABLE OF CONTENTS QUICK SEARCH: [advanced] Author: Keyword(s): Year: Vol: Page: This Article Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal ... Cited by other online articles PubMed PubMed Citation Articles by Van Den Heuvel, A. G. Articles by Mali, W. P. ARTICLES Differentiation between portal-systemic encephalopathy and neurodegenerative disorders in patients with Wilson disease: H-1 MR spectroscopy AG Van Den Heuvel, J Van der Grond, LG Van Rooij, HN Van Wassenaer-van Hall, TU Hoogenraad and WP Mali Department of Radiology, University Hospital Utrecht, The Netherlands. PURPOSE: To investigate the extent to which neurodegeneration and metabolic changes caused by portosystemic shunting occur in Wilson disease. MATERIALS AND METHODS: Twenty-two adult patients with biochemically proved Wilson disease underwent magnetic resonance (MR) imaging, hydrogen-1 MR

45. Portal-systemic Encephalopathy: Presence Of Basal Ganglia Lesions With High Sign portalsystemic encephalopathy presence of basal ganglia lesions with high signalintensity on MR images. E Inoue, S Hori, Y Narumi, M Fujita, K Kuriyama, http://radiology.rsnajnls.org/cgi/content/abstract/179/2/551

HOME HELP FEEDBACK SUBSCRIPTIONS ... TABLE OF CONTENTS QUICK SEARCH: [advanced] Author: Keyword(s): Year: Vol: Page: This Article Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted ... Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal ... Cited by other online articles PubMed PubMed Citation Articles by Inoue, E. Articles by Kuroda, C. ARTICLES Portal-systemic encephalopathy: presence of basal ganglia lesions with high signal intensity on MR images E Inoue, S Hori, Y Narumi, M Fujita, K Kuriyama, T Kadota and C Kuroda Department of Diagnostic Radiology, Center for Adult Diseases, Osaka, Japan. Sixteen patients with cirrhosis of the liver underwent cranial magnetic resonance (MR) imaging and transarterial portography to evaluate the relationship between basal ganglia lesions and portal-systemic collateral vessels. No neuropsychiatric disturbance was observed in any of the

46. Conventional Interferon Therapy Has Little Effect On The Progression Of Portal H of treated and 3.1% of untreated developed portalsystemic encephalopathy and11.9% variceal bleeding and portal-systemic encephalopathy occurrence. http://www.hivandhepatitis.com/2004icr/39easl/documents/0503/050504_hcv_a.html

Internet Conference Report 39th EASL - April 14 - 18, 2004, Berlin Germany Conventional Interferon Therapy Has Little Effect on the Progression of Portal Hypertension in HCV-related Cirrhosis The effect of IFN therapy on complications of HCV-related cirrhosis is not fully understood. There are data indicating that hepatocellular carcinoma (HCC) might be prevented or delayed, while much less clear is the effect on portal hypertension and esophageal varices. Italian researchers conducted a long-term follow-up study of 380 consecutive patients with compensated HCV-related cirrhosis. 185 patients were treated with one or more courses of IFN therapy, while 195 remained untreated. All patients were followed-up with periodical (every 6 months) evaluation and abdominal ultrasound and with periodical (every 12-24 months) esophagogastroduodenoscopy. Results During a mean follow-up period of 88.8 ± 42.0 months, 15.1% of IFN treated and 22.6% of untreated patients developed HCC, 19.8% of treated and 24.8% of untreated showed esophageal varices appearance or worsening, 11.9% of treated and 19.5% of untreated developed ascites, 3.8% of treated and 5.6% of untreated had variceal bleeding, 1.1% of treated and 3.1% of untreated developed portal-systemic encephalopathy and 11.9% of treated and 20.9% of untreated patients dead from liver-related causes.

47. Current Opinion In Clinical Nutrition And Metabolic Care - UserLogin OrnithineL-aspartate in experimental portal-systemic encephalopathy therapeuticefficacy and mechanism of action. Metab Brain Dis 1998; 13147-157. http://www.co-clinicalnutrition.com/pt/re/conutrition/fulltext.00075197-19990100

LWWOnline LOGIN eALERTS REGISTER ... Archive You are attempting to access protected content. To access this content please login using an established account or create/activate an account. If you have already created/ activated an online account, please login below: User Name: Password: Note: passwords are CASE SENSITIVE If you are a new user or guest visiting an LWWonline site for the first time, please complete the new account setup process to view or purchase content. Forgot your password? Subscribe Renewal Information Subscribe to RSS feed utrdc-pt02 Release 4.0

48. Numark | Liver Cirrhosis called portalsystemic encephalopathy (PSE), which may lead to coma. in chronic portal-systemic encephalopathy a randomized controlled trial. http://www.numarkpharmacists.com/hn/Concern/Liver_Cirrhosis.htm

Site Search Your Local Pharmacy Conditions A to Z Acne Alopecia Alzheimer's Disease Anorexia Nervosa Anxiety Arthritis Asthma Athlete's Foot Breast Cancer Bulimia Nervosa Cholesterol Cluster Headaches Cold Sores Constipation Cystitis Dandruff Depression Diabetes Diarrhoea Dry Skin Eczema Endometriosis Epilepsy Haemorrhoids Hayfever Heart Disease Heartburn Heavy Periods Huntington's Disease Impotence Incontinence Indigestion Insomnia Manic Depression Menopause Migraine Mouth Ulcers Prostate Cancer Psoriasis Scalp Psoriasis Stress Tonsillitis Trichotillomania Ulcerative Colitis Vaginal Itching Vaginal Thrush Warts Health News Disability Men's Health Women's Health ... Contact us Liver Cirrhosis Liver Cirrhosis Also indexed as: Liver Cirrhosis, Liver Disease Skip to: About Checklist Symptoms Treatments ... References Cirrhosis is a condition of severe damage to the liver that impairs its ability to function normally. In the United States, the most common cause of liver cirrhosis is chronic alcoholism . Liver cirrhosis may also result from chronic viral infection of the liver ( hepatitis types B, C, and D) and a number of inherited diseases, such as

49. GNC - HealthNotes - Liver Cirrhosis disease and cancer).1 Liver cirrhosis may also cause a dangerous brainabnormality called portalsystemic encephalopathy (PSE), which may lead to coma. http://www.gnc.com/health_notes/healthnotes.aspx?ContentID=1231004

50. Bulletin Of Russian Peoples Friendship University PORTAL SYSTEMIC ENCEPHALOPATHY AND DIURETIC THERAPY IN PATIENTS WITH Diuretic therapy complicated with portalsystemic encephalopathy in 25,9% of http://med.pfu.edu.ru/_new/english/win/library/vestnik/v991e/09.htm

Bulletin of Russian Peoples Friendship University. "Medicine" PORTAL SYSTEMIC ENCEPHALOPATHY AND DIURETIC THERAPY IN PATIENTS WITH ALCOHOLIC LIVER CIRRHOSIS N.D.KISLIY, M.MULLA OSMAN, N.N.OMELCHUK, G.R.ZLATINSKAJA Department of Hospital Therapy RPFU. Moscow. 117198. M-Maklaya st 8. Medical faculty P.N.POPOV, S.A.AZEVICH, S.M.SCHEMILCHANOVA Municipal Hospital N 53. Moscow. 109432. Trofimova st 26. 357 patients (216 men and 141 women) with alcoholic liver cirrhosis were studied. Their mean age was 50,5 0,6 years. Portal-systemic encephalopathy were in 34,1% of patients. Diuretic therapy complicated with portal-systemic encephalopathy in 25,9% of patients with alcoholic liver cirrhosis. Grade of portal-systemic encephalopathy correlate with quantity of hemoglobin, red cells, albumin, urea, creatinine and bilirubin.

51. INABIS '98 - The Effect Of Portacaval Anastomosis On Hippocampal EEG Activity functions is a classic symptom of portalsystemic encephalopathy in humans . intellectual function in patients with portal-systemic encephalopathy. http://www.mcmaster.ca/inabis98/behavneuro/lozeva0424/two.html

Behavioural Neuroscience Poster Session Abstract Introduction Results References ... New Search The Effect of Portacaval Anastomosis on Hippocampal EEG Activity Contact Person: Violina Lozeva ( violina.lozeva@uku.fi Introduction Impairment of intellectual functions is a classic symptom of portal-systemic encephalopathy in humans. The hippocampal system is important for learning and memory both in humans and animals. Different subcortical neurotransmitter systems participate in the regulation of hippocampal activity and thus play a role in the cognitive process. It has been suggested that endogenous histamine, particularly neuronal histamine in the hippocampus and hypothalamus, may be involved in the process of learning and memory in rats. Long-term portacaval anastomosis in the rat results in dramatic, region-selective changes in the brain histamine system, characterized by a marked increase in the tissue levels and a moderate elevation in the extracellular concentrations of histamine, and an increase in the tissue concentrations of tele -methylhistamine, most evident in the hypothalamus.

52. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques - UserLogin Watanabe A. portalsystemic encephalopathy in non-cirrhotic patients classificationof portal-systemic encephalopathy due to a congenital extrahepatic http://www.surgical-laparoscopy.com/pt/re/slept/fulltext.00129689-200410000-0001

LWWOnline LOGIN eALERTS REGISTER ... Archive You are attempting to access protected content. To access this content please login using an established account or create/activate an account. If you have already created/ activated an online account, please login below: User Name: Password: Note: passwords are CASE SENSITIVE If you are a new user or guest visiting an LWWonline site for the first time, please complete the new account setup process to view or purchase content. Forgot your password? Subscribe Renewal Information Subscribe to RSS feed utrdc-pt01 Release 4.0

53. Journal Of Pediatric Gastroenterology And Nutrition - UserLogin portalsystemic encephalopathy due to congenital intrahepatic shunts. Portal systemic encephalopathy presenting with dressing and constructional apraxia http://www.jpgn.org/pt/re/jpgn/fulltext.00005176-200410000-00019.htm

54. - Lucile Packard Children's Hospital Liver encephalopathy is also called portalsystemic encephalopathy, hepaticencephalopathy, or hepatic coma. Symptoms may include http://www.lpch.org/DiseaseHealthInfo/HealthLibrary/digest/livdisea.html

Clinical Nutrition Gastroenterology, Nutrition and Hepatology Liver Transplantation Gastroenterologists ... Transplantation Digestive and Liver Disorders What are some common liver disease symptoms? When diagnosing liver disease, the physician looks at the patient's symptoms and conducts a physical examination. In addition, the physician may request a liver biopsy, liver enzyme tests, an ultrasound, or a CT scan (computed tomography scan). Some common liver disease symptoms include the following, each of which are described briefly below: jaundice cholestasis liver enlargement portal hypertension ascites liver encephalopathy liver failure What is jaundice? Jaundice is a yellow discoloration of the skin and whites of the eyes due to an abnormally high level of bilirubin (bile pigment) in the bloodstream, which is then excreted through the kidneys. High levels of bilirubin may be attributed to inflammation or other abnormalities of the liver cells, or blockage of the bile ducts. Sometimes jaundice is caused by the breakdown of a large number of red blood cells, which can occur in newborns. Jaundice is usually the first sign, and sometimes the only sign, of liver disease. What is cholestasis?

55. IM Abstract 40-8 Original Article 1 on portalsystemic encephalopathy in Patients with Liver Cirrhosis chronic recurrent hepatic encephalopathy due mainly to a portal-systemic shunt. http://www.naika.or.jp/im/im40/ab4008/o400801.html

Home Table of Issues Vol.40 No.8 Therapeutic Effect of Balloon-occluded Retrograde Transvenous Obliteration on Portal-systemic Encephalopathy in Patients with Liver Cirrhosis Objective Balloon-occluded retrograde transvenous obliteration (B-RTO) has recently been introduced as a new interventional modality to prevent fatal bleeding from solitary gastric varices. A large portal-systemic shunt including gastric varices also causes severe encephalopathy in some cirrhotic patients. In this study, we evaluated the effect of B-RTO as a candidate therapeutic method to treat chronic recurrent hepatic encephalopathy due mainly to a portal-systemic shunt. Patients and Methods Results In all 6 patients, encephalopathy had disappeared after B-RTO, and the patients were free of encephalopathy during the following 6 months. B-RTO significantly reduced blood ammonia levels at one month, 3 months, and 6 months later, without affecting serum aspartate aminotransferase activity, total bilirubin and albumin concentrations, and plasma prothrombin time. Encephalopathy relapsed in 4 patients between 6 and 30 months. Additional B-RTO was required and effective in 2 of them. Conclusion B-RTO is an effective treatment for chronic recurrent hepatic encephalopathy with an angiographically proven portal-systemic shunt.

56. Cerebral Blood Flow Velocity In Patients With Subclinical Portal- Systemic Encep flow (CBF) are implicated in the etiology of portalsystemic encephalopathy . (CLD) who also had subclinical portal-systemic encephalopathy (SPSE). http://www.anesthesia-analgesia.org/cgi/content/abstract/86/5/1005

HOME HELP FEEDBACK SUBSCRIPTIONS ... TABLE OF CONTENTS QUICK SEARCH: [advanced] Author: Keyword(s): Year: Vol: Page: This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal ... Download to citation manager PubMed PubMed Citation Articles by Katz, J. J. Articles by Zamudio, S. GENERAL ARTICLES Cerebral blood flow velocity in patients with subclinical portal- systemic encephalopathy JJ Katz, MS Mandell, RM House, BM Bilir, B Barton and S Zamudio Department of Anesthesiology, University of Colorado Health Sciences Center, Denver 80262, USA. Alterations in cerebral blood flow (CBF) are implicated in the etiology of portal-systemic encephalopathy. We hypothesized that CO2 reactivity of the cerebral circulation may be impaired in subjects with chronic liver disease (CLD) who also had subclinical portal-systemic encephalopathy (SPSE). We compared the relationship between PETCO2 and cerebral blood flow velocity in 10 patients with CLD with those of 10 healthy control subjects. Middle

57. Arq. Neuro-Psiquiatr.  Vol.57 no.2A; Abstract: S0004-282X1999000200024 Keywords mansonic schistosomiasis; portalsystemic encephalopathy; basal ganglia;manganese; neuroradiology; magnetic resonance image. http://www.scielo.br/scielo.php?pid=S0004-282X1999000200024&script=sci_abstract&

58. Brazilian Journal Of Medical And Biological Research - Neuropsychological aspects of portalsystemic encephalopathy. Metabolic BrainDisease, 12 361-367. 9. Rehnstrom S, Simert G, Hansson JA, Johnson G Vang J http://www.scielo.br/scielo.php?pid=S0100-879X2005000100019&script=sci_arttext&t

59. CV: Vemuganti amino acids in relation to function in portalsystemic encephalopathy Results of in brain in human and experimental portal-systemic encephalopathy. http://www.neurosurg.wisc.edu/cvvem.htm

University of Wisconsin Department of Neurological Surgery CURRICULUM VITAE Raghavendra Rao L. Vemuganti Assistant Scientist Dept. of Neurological Surgery University of Wisconsin-Madison F4/309 Clinical Science Center 600 Highland Avenue Madison, WI 53792, USA Education 1982 B.Sc., Zoology, Botony and Chemistry, Andhra University, India 1984 M.Sc., Life Sciences (Animal Sciences), University of Hyderabad, India 1986 M.Phil., Life Sciences (Neurochemistry), University of Hyderabad, India 1991 Ph.D. Life Sciences (Neurochemistry), University of Hyderabad, India Fellowships 1984-1985 M.Phil. Fellowship, University of Hyderabad, India 1989-1991 Senior Research Fellowship award, Indian Council of Medical Research, India 1992-1993 Post-doctoral Fellowship Medical Research Council of Canada funded project 1993-1994 Post-doctoral Fellowship award, Jasper Foundation, University of Montreal 1993-1996 Medical Research Council of Canada, Direct Post-doctoral Fellowship Awards 1989 Best poster award, Indian Academy of Neuroscience Annual Meeting, Calcutta, India

60. Current Opinion In Gastroenterology - UserLogin portalsystemic encephalopathy TOP. Manganese is among the potential neurotoxins implicated in the pathogenesis of portal-systemic encephalopathy (PSE). http://www.co-gastroenterology.com/pt/re/cogastro/fulltext.00001574-200005000-00

LWWOnline LOGIN eALERTS REGISTER ... Archive You are attempting to access protected content. To access this content please login using an established account or create/activate an account. If you have already created/ activated an online account, please login below: User Name: Password: Note: passwords are CASE SENSITIVE If you are a new user or guest visiting an LWWonline site for the first time, please complete the new account setup process to view or purchase content. Forgot your password? Subscribe Renewal Information Subscribe to RSS feed utrdc-pt02 Release 4.0

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 3     41-60 of 102    Back | 1  | 2  | 3  | 4  | 5  | 6  | Next 20